Frank Rhame, MD
Infectious Disease · Minneapolis, MNNPI 1811959901
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $90,230 of the $131,502 with a category attached, or 68.6%. Viiv Healthcare Company accounts for 73.7% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $87,125 and has fallen 97.8% since, to $1,925 in 2024. Among infectious disease clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 143 payments — averaging $919.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$97K
- Gilead$33K
- Diasorin Inc.$2K
- Astellas Pharma US Inc$50
Across 95 payments — averaging $31,836 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$2.7M
- Eli Lilly$175K
- Pfizer$62K
- Diasorin Inc.$47K
- Merck$30K
- Gilead$24K
- plus $4K from 1 others
What the payments were for
- Consulting fees$21,81517%
- Speaking & faculty fees$90,23069%
- Travel & lodging$17,19413%
- Food & beverage$2,2632%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 93 | $96,956 |
| Gilead | 48 | $32,572 |
| Diasorin Inc. | 1 | $1,925 |
| Astellas Pharma US Inc | 1 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$131,502 in reported general payments places this provider in the 95th percentile of 157 infectious disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 276 | $1,130,148 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 199 | $823,670 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 156 | $640,623 |
| DovatoDolutegravir Sodium/Lamivudine | 177 | $562,061 |
| TivicayDolutegravir Sodium | 138 | $316,554 |
| DescovyEmtricitabine/Tenofov Alafenam | 131 | $297,401 |
| JulucaDolutegravir/Rilpivirine | 67 | $267,751 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 33 | $125,613 |
| IsentressRaltegravir Potassium | 26 | $55,290 |
| OzempicSemaglutide | 33 | $33,335 |
| PrezcobixDarunavir/Cobicistat | 11 | $27,178 |
| MicafunginMicafungin Sodium | 11 | $13,651 |
| EliquisApixaban | 12 | $10,954 |
| Darunavir | 29 | $10,128 |
| XareltoRivaroxaban | 12 | $6,773 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $32,572 | $2,251,219606 claims |
| Viiv Healthcare CompanyDovato, Tivicay, Juluca, Triumeq | $96,956 | $1,271,979415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 157 infectious disease providers in Minnesota.
Other infectious disease in Minneapolis
- William HenryMinneapolis$7K
- William StaufferMinneapolis$5K
- Grishma TrivediMinneapolis$3K
- Alison BormannMinneapolis$3K
- Karam ObeidMinneapolis$3K
- Jo Anne YoungMinneapolis$2K
- David BoulwareMinneapolis$2K
- Michele GranadaMinneapolis$430
- Christian SchrockMinneapolis$230
- Daniel ShapiroMinneapolis$178
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.